151 related articles for article (PubMed ID: 4005120)
1. A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers.
Woods KL; Jack DB; Kendall MJ; Halsey A; O'Donnell ML; Warrington SJ; John VA
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):177S-184S. PubMed ID: 4005120
[TBL] [Abstract][Full Text] [Related]
2. Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers.
Bennett PN; Bennett J; Bradbrook I; Francis J; John VA; Rogers H; Turner P; Warrington SJ
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):171S-175S. PubMed ID: 4005119
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of oxprenolol following oral and rectal dosing--a comparison of delivery systems and routes of administration.
Gregg MR; Jack DB; Smith SR; Kendall MJ
J Clin Pharm Ther; 1987 Apr; 12(2):91-9. PubMed ID: 3584272
[TBL] [Abstract][Full Text] [Related]
4. Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily.
Müller FB; Allsopp LF; Cooper GL; Bolli P; Frei P; Glaus L; Ritz R; Bühler FR
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):207S-212S. PubMed ID: 4005124
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.
McInnes GT; Brodie MJ
Eur J Clin Pharmacol; 1988; 34(6):605-11. PubMed ID: 3169112
[TBL] [Abstract][Full Text] [Related]
6. Pre-dosing plasma concentrations and beta-adrenoceptor blocking effects during repeated once daily dosing with 160 mg sustained-release propranolol (Inderal LA) and 16/260 oxprenolol Oros to healthy volunteers.
Moppert J; Degen PH; Racine-Poon A
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):197S-201S. PubMed ID: 2988591
[TBL] [Abstract][Full Text] [Related]
7. A multiple dose pharmacokinetic and pharmacodynamic evaluation of conventional and 19/285 Oros formulations of metoprolol in healthy volunteers.
Grainger SL; John VA; Shotton PA; Smith SE
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):239S-244S. PubMed ID: 4005129
[TBL] [Abstract][Full Text] [Related]
8. Twenty-four hour effects of oxprenolol Oros and atenolol on heart rate, blood pressure, exercise tolerance and perceived exertion.
van Baak MA; Verstappen FT; Oosterhuis B
Eur J Clin Pharmacol; 1986; 30(4):399-406. PubMed ID: 3743615
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release.
Bradbrook ID; John VA; Morrison PJ; Rogers HJ; Spector RG
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):163S-169S. PubMed ID: 4005118
[TBL] [Abstract][Full Text] [Related]
10. Reproducibility of oxprenolol plasma concentrations in young female volunteers following oral administration of an oxprenolol Oros dosage form.
Jack DB; Kendall MJ; Laugher SJ; Smith SR
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):185S-190S. PubMed ID: 4005121
[TBL] [Abstract][Full Text] [Related]
11. Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise.
Bobik A; Jennings GL; Korner PI; Ashley P; Jackman G
Br J Clin Pharmacol; 1979 Jun; 7(6):545-9. PubMed ID: 465276
[TBL] [Abstract][Full Text] [Related]
12. Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects.
Bradbrook ID; Babiker M; Crome P; Gillies HC; Morrison PJ; Rogers HJ; Shotton P
Br J Clin Pharmacol; 1986 Apr; 21(4):371-6. PubMed ID: 3707811
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the beta-adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation.
Kerr MJ; Harron DW; Kinney C; Shanks RG
Br J Clin Pharmacol; 1981 Dec; 12(6):869-71. PubMed ID: 6122463
[TBL] [Abstract][Full Text] [Related]
14. A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects.
West MJ; Kendall MJ; Mitchard M; Faragher EB
Br J Clin Pharmacol; 1976 Jun; 3(3):439-43. PubMed ID: 788749
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers.
Aellig WH
Eur J Clin Pharmacol; 1978 Nov; 14(3):167-9. PubMed ID: 729611
[TBL] [Abstract][Full Text] [Related]
16. Influence of food intake on plasma oxprenolol concentrations following oral administration of conventional and Oros preparations.
John VA; Smith SE
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):191S-195S. PubMed ID: 4005122
[TBL] [Abstract][Full Text] [Related]
17. Comparison of single-dose pharmacokinetic and pharmacodynamic properties of two metoprolol Oros systems with different initial zero-order release rates.
Warrington SJ; Barclay SP; John VA; Shotton PA; Good W
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):225S-230S. PubMed ID: 4005127
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of oxprenolol in normal subjects.
Mason WD; Winer N
Clin Pharmacol Ther; 1976 Oct; 20(4):401-12. PubMed ID: 10124
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinical effects of propranolol (Inderal) with once daily slow-release oxprenolol (Slow Trasicor) in angina pectoris.
Majid PA; de Feijter PJ; Wardeh R; van der Wall EE; Roos JP
J Int Med Res; 1979; 7(3):194-200. PubMed ID: 378729
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of oxprenolol slow release and osmotic release by exercise testing and ambulatory electrocardiographic monitoring in patients with chronic stable angina pectoris.
Bowles MJ; Khurmi NS; O'Hara MJ; Raftery EB
Eur J Clin Pharmacol; 1987; 32(2):127-33. PubMed ID: 3556193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
